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Abstract
Background Despite the benefits offered by biosimilars in terms of cost savings and improved patient access to biological 
therapies, and an established regulatory pathway in Europe, biosimilar adoption is challenged by a lack of knowledge and 
understanding among stakeholders such as healthcare professionals and patients about biosimilars, impacting their trust 
and willingness to use them. In addition, stakeholders are faced with questions about clinical implementation aspects such 
as switching.
Objective This study aims to provide recommendations on how to improve biosimilar understanding and adoption among 
stakeholders based on insights of healthcare professionals (physicians, hospital pharmacists, nurses), patient(s) (representa-
tives) and regulators across Europe.
Method The study consists of a structured literature review gathering original research data on stakeholder knowledge about 
biosimilars, followed by semi-structured interviews across five stakeholder groups including physicians, hospital pharmacists, 
nurses, patient(s) (representatives) and regulators across Europe.
Results Although improvement in knowledge was observed over time, generally low to moderate levels of awareness, knowl-
edge and trust towards biosimilars among healthcare professionals and patients are identified in literature (N studies = 106). 
Based on the provided insights from interviews with European experts (N = 44), a number of challenges regarding biosimilar 
stakeholder understanding are identified, including a lack of practical information about biosimilars and their use, a lack of 
understanding about biosimilar concepts and a lack of knowledge about biologicals in general. Misinformation by originator 
industry is also believed to have impacted stakeholder trust. In terms of possible solutions and actions to improve stakeholder 
understanding, broad support exists to (1) organize initiatives focussed on explaining the rationale behind biosimilar concepts 
and the approval pathway, (2) invest in education about biologicals in general, (3) develop clear and one-voice regulatory 
guidance about biosimilar interchangeability and switching across Europe, (4) disseminate real-world clinical biosimilar 
(switch) data, (5) share biosimilar experiences by key opinion leaders and among peers, (6) provide practical biosimilar 
product information, (7) provide guidance about biosimilar use, (8) actively counterbalance misinformation and organize 
information initiatives by neutral entities, (9) organize multi-stakeholder informational and educational efforts, aligning 
information between involved stakeholder groups and (10) design initiatives in a way that ensures active information uptake. 
Furthermore, interviewees argue that governments should be proactive in these regards.
Conclusions This study argues in favour of a structural, multi-stakeholder framework at both European and national level 
to improve stakeholder biosimilar understanding and acceptance. It proposes a number of actionable recommendations that 
can inform policy making and guide stakeholders, which can contribute to realizing healthcare system benefits offered by 
biosimilar competition.
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article (https ://doi.org/10.1007/s4025 9-020-00452 -9) contains 
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Key Points 
biosimilars, as uptake has also been challenged by discouraging 
procurement processes, lack of stakeholder motivation and stake-
holder uncertainties about interchangeability and switching [6, 7].
This study, the first in a series of two, aims to provide 
recommendations on how to improve biosimilar understand-
ing and acceptance based on a structured literature review 
and insights from expert interviewees (physicians, hospital 
pharmacists, nurses, patient[s] [representatives] and regula-
tors) across Europe.
The second article in this series assesses multi-stake-
holder insights on how to improve biosimilar use in clinical 
practice [8].
2  Methods
This study consists of a structured literature review and 
semi-structured interviews with expert stakeholders.
2.1  Structured Literature Review
A structured literature review was carried out to identify 
HCPs’ and patients’ knowledge about biosimilars. PubMed 
was searched up to the 4th of January 2020 by combining 
search terms on biosimilars, HCPs, patients and knowledge 
(see Electronic Supplementary Material [ESM] 1). Search 
results were screened based on predefined inclusion and 
exclusion criteria (see ESM 2). The inclusions were further 
supplemented by grey literature.
Original research studies describing the knowledge and 
understanding of HCPs or patients about biosimilars and 
biosimilar-related concepts were included. Articles describ-
ing expert opinions or position statements were excluded. 
Study parameters and results were systematically extracted.
2.2  Semi‑Structured Interviews
Interviews with experts were conducted across five stake-
holder groups (physicians, hospital pharmacists, nurses, 
patients and regulators) to obtain multi-stakeholder insights 
on how to improve knowledge and understanding about bio-
similars among HCPs and patients. Experts were recruited 
across Europe and where possible from European organiza-
tions or institutions (e.g. representatives of European stake-
holder associations) to capture pan-European perspectives. 
HCPs and patients were recruited across disease domains 
currently relevant for biosimilars. Participants were identi-
fied by screening websites of stakeholder associations and 
regulatory authorities, conference speakers, authors of bio-
similar literature and the research group’s network.
The interview questions were based on topics identified 
in the literature (see ESM 3). The interview questions were 
tested in three pilot interviews.
Healthcare professionals and patients have shown low 
to moderate awareness, knowledge and trust towards 
biosimilars in previous research; this underlines the need 
for continued efforts to improve biosimilar understand-
ing among stakeholders.
This article proposes a structural, multi-stakeholder 
framework with actionable recommendations aimed at 
informing policymakers and guiding stakeholders to 
improve biosimilar understanding.
A coordination of efforts between the different involved 
stakeholders is needed to capture the societal and patient 
benefits offered by biosimilars.
1 Introduction
Following loss of exclusivity of original biological medi-
cines, highly similar versions—biosimilars—can enter the 
market. Biosimilars are approved according to the same 
standards of quality, safety and efficacy as any biological and 
need to demonstrate that any differences to their reference 
product are not clinically meaningful [1]. Biosimilars can 
partly rely on data that have been gathered for the reference 
product, allowing tailoring of their clinical development, 
leading to lower development costs and subsequent prices 
[2]. Biosimilars pose a timely opportunity to relieve budget-
ary pressured healthcare systems, as the price competition 
introduced by biosimilars has been recognized to signifi-
cantly impact overall medicine expenditure. Further, biosim-
ilar market access has shown to increase patient access to 
these formerly expensive biological therapies [3, 4].
Since the establishment of a regulatory approval path-
way in 2004 and the first biosimilar approval in 2006 in 
Europe [2], more than 55 biosimilars for 15 distinct refer-
ence products have been approved, accumulating to more 
than 15 years of regulatory and clinical experience with bio-
similars [5]. Although the arrival of biosimilars has shown 
to provide benefits on a societal and patient level, so far 
biosimilar market shares have varied across European coun-
tries and products, and were in some cases limited. Gaps in 
knowledge and understanding about biosimilars and their 
regulatory approval process among healthcare professionals 
(HCPs) and patients may limit biosimilar acceptance and 
curb their use [6, 7].
In addition to improving stakeholder understanding, other 
measures may be needed to fully capture the potential of 
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The interviews were carried out between October 2017 
and June 2018. Interviews were conducted in English, with 
the exception of a few interviews in Dutch based on the 
interviewee’s preference. The interviews were conducted by 
 Skype®, phone or in person and digitally audio-recorded. 
Participation was voluntary and interviewees did not receive 
any remuneration.
The recordings were transcribed ad verbatim. The tran-
scripts were pseudonymized and analysed according to the 
thematic framework method using NVivo  software® [9].
3  Results
3.1  Literature Review—Mapping Knowledge 
and Trust Levels of Healthcare Professionals 
and Patients
The screening and selection of 383 identified records led to 
the inclusion of 100 studies. Additionally, six studies were 
identified in grey literature, resulting in a total of 106 stud-
ies reporting original research on HCPs’ and/or patients’ 
biosimilar perceptions. With the exception of a few studies 
involving focus group discussions, interviews or expert pan-
els, studies consisted of a survey. The perspectives of phy-
sicians and patients were surveyed the most (N = 37, 35% 
and N = 32, 30%, respectively, versus pharmacists: N = 10, 
10%; nurses: N = 1, 1%; across stakeholder groups: N = 26, 
25%). Approximately one third of the studies were either 
industry sponsored (N = 8, 8%) or conducted by industry 
(N = 28, 26%). The characteristics of the included studies 
are shown in Fig. 1.
Although improvements were observed over time, gaps 
in knowledge and understanding about biosimilars and reg-
ulatory concepts were generally identified across regions, 
therapeutic areas and stakeholder groups. Overall, voiced 
concerns across studies included questions about biosimi-
lar immunogenicity, safety, efficacy, interchangeability, 
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Fig. 1  Structured literature review—characteristics of studies on 
stakeholder knowledge and perceptions about biosimilars (N = 106). 
a Studies categorized per stakeholder group, b Studies categorized 
per region, c Studies categorized per therapeutic area, d Studies 
categorized per publication year, e Studies categorized per reported 
conflict of interest/funding type. A: no declared conflict of interest, 
B: declared author conflict of interest (or disclosure of interest) (e.g. 
HCPs/academics providing advice/paid consultancy to industry), C: 
industry sponsoring/educational grant from industry to support inde-
pendent research declared, D: research conducted by industry/lobby 
organization/consultancy, E: potential funding/conflict of interest not 
specified, f Studies categorized per number of participants. Derm der-
matology, Endocr endocrinology, Gastro-ent gastro-enterology, GP 
general practice, N number, Onco/hemato oncology, haematology, 
Rheum Rheumatology, ROW rest of the world, US United States
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Various studies identified that, if presented with a choice, 
patients would object to being switched or physicians would 
object to switching their patients to a biosimilar [19, 20]. In 
contrast, patients who were switched generally reported a 
positive experience, suggesting that experience with biosim-
ilars leads to increased trust [21, 22]. Additionally, concerns 
existed among stakeholders about being forced to switch or 
being limited in prescription choice [23–26].
In several studies, physicians showed willingness to use 
biosimilars if this would result in increased patient access to 
treatment or in reduced healthcare costs [27, 28]. A survey 
among Hungarian oncologists and haematologists showed 
that prescribers would increase rituximab use if a biosimilar 
were available, as 40% considered patient access to rituxi-
mab an issue [29].
Patients appear to heavily rely on the physician’s deci-
sion to use a biosimilar, as identified across multiple studies 
[16, 30–36]. Among suggested solutions to improve patients’ 
biosimilar acceptance, communication and reassurance from 
HCPs, together with involvement in decision making, were 
mentioned [37]. A New Zealand survey identified the need 
among physicians for guidance on how to explain biosimilar 
treatment to patients [38].
Although earlier reports and the overall literature 
identified relatively low to moderate levels of knowledge 
and acceptability of biosimilars among stakeholders, 
improvements over time were identified. A survey conducted 
in 2013 among European Crohn’s and Colitis Organisation 
(ECCO) members reported that the majority of inflamma-
tory bowel disease (IBD) specialists had little or no con-
fidence about biosimilar use, expressing various concerns 
[10]. In 2015, ECCO repeated the survey, reporting fewer 
concerns and more confidence about biosimilar use among 
participants. IBD specialists were generally well informed 
and educated about biosimilars compared with the 2013 data 
[39]. Although improvements in stakeholder knowledge 
were mentioned in some studies, recent studies such as the 
European Federation of Crohn’s and Ulcerative Colitis Asso-
ciation patient member survey published in 2019 signalled 
that awareness remains limited and stakeholders, in this case 
patients, continue to have concerns [40].
Recommendations on how to improve stakeholder accept-
ance mentioned in the literature included adapting clinical 
guidelines to reflect biosimilar use, implementing clear 
communication between physicians and patients, sharing 
real-world data with HCPs and educating prescribers about 
switch study data [41–44]. A few studies demonstrated that 
training stakeholders considerably improved their under-
standing and confidence in biosimilars [45, 46].
A structured overview of the original research studies 
about HCPs’ and patients’ biosimilar perspectives, including 
study parameters and main results, is given in the ESM 4.
Part II
• Lack of understanding about biosimilar concepts
and the biosimilar regulatory approval pathway
(e.g. perceived lack of clinical trials)
• Lack of knowledge about biologicals in general
(e.g. low awareness about existence of product
variability, misconceptions about
immunogenicity)
• Differences in approach and guidance (USA vs
EU vs Member States) regarding
interchangeability and switching
• Lack of clear and ready to use guidance about
biosimilar use e.g. switch guidance
• Lack of practical and timely product information
(e.g. on biosimilar pipeline, product features,
practical implications for the patient)
• Misrepresentation of information and industry
influence, leading to misconceptions and
hindering effective communication
• Lack of effective dissemination and active uptake
of the available information
• Possible evidence generation hurdles for
biosimilar developers to respond to stakeholder
requests for additional clinical data beyond the
biosimilar licensing requirements, driven by
stakeholder uncertainty and missing stakeholder
guidance
Stakeholder challenges Stakeholder aligned recommendations
• Implement education about biologicals (including
biosimilars) in curricula and continued professional
learning programs of HCPs, ensuring active training
and information uptake
• Provide biosimilar product horizon scanning and
structured product overviews, with information about
characteristics of available products (reference product
and available biosimilars) (similarities and differences
in e.g. approved indications, device,…)
• Educate hospital-stakeholders on how to organize
procurement (e.g. application of selection criteria)
• Stimulate active collaboration between regulatory
authorities and professional stakeholder associations to
• draft and actively disseminate tailored and
independent information in line with regulatory
message to target audience (e.g. by writing and
updating position papers)
• organize multi-stakeholder education initiatives
• orchestrate actions between involved parties to
ensure effective information flows
• Communicate across different therapeutic areas and
disciplines, leveraging and exchanging insights and
experiences of previous ‘biosimilar-exposed’ specialties
• Continue information provision about rationale behind
the regulatory approval pathway with a focus on
actively disseminating materials, e.g. leveraging EMA’s
biosimilar stakeholder guidance documents on a
national/local level
• Stimulate collaboration between EU and national
agencies to ensure one-voice regulatory information
and guidance regarding interchangeability and
switching
• Monitor and correct biosimilar misinformation
• Raise awareness about EPAR as product information
tool and routinely update the EPAR over time
Actions by national governments and policy makers 
Multi-stakeholder actions Actions by regulators 
• Provide biosimilar position statements, endorsing
regulatory concepts and associated messages, and
update these over time
• Adapt clinical guidelines to reflect biosimilar use
• Translate regulatory information to the practical context
relevant for HCPs and patients (e.g. to disease domain,
hospital/ambulatory setting)
• Appoint biosimilar educators to guide biosimilar
implementation in clinical practice
• Communicate biosimilar experiences among peers
• Disseminate real-world-biosimilar (switch) data
Actions by HCPs and stakeholder associations
Fig. 2  How to improve stakeholder understanding about biosimilars—proposed multi-stakeholder actions. EMA European Medicines Agency, 
EPAR European Public Assessment Report, HCPs healthcare professionals, NCAs national competent authorities
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3.2  Semi‑Structured Interviews—Identifying 
Challenges and Actions to Improve HCP 
and Patient Understanding and Trust 
in Biosimilars
In total, 44 interviews were carried out. Participant charac-
teristics are shown in ESM 5 and 6.
Overarching identified stakeholder challenges and pro-
posed actions to improve stakeholder understanding and 
acceptance of biosimilars are shown in Fig. 2.
3.2.1  Improving Stakeholder Understanding About 
Regulatory Biosimilar Concepts
A lack of stakeholder knowledge and understanding of regu-
latory biosimilar concepts was identified as an important 
hurdle by most interviewees. Communication about the bio-
similar regulatory approval pathway, reducing misconcep-
tions about the biosimilarity concept, was deemed essential. 
Regulators emphasized that they have undertaken actions 
to improve stakeholder understanding about biosimilars, 
including the development and dissemination of informa-
tional materials in lay language for HCPs and patients, 
and the publication of biosimilar concept papers. Several 
interviewees mentioned that the robustness of the regula-
tory approval procedure should be emphasized in biosimilar 
stakeholder information.
3.2.1.1 Explaining the  Rationale Behind Regulatory Bio‑
similar Evaluation to Address the Perceived Lack of Clinical 
Data Across physician, pharmacist and regulator interview-
ees, it was generally recognized that the physicians’ under-
standing about the reduced role of clinical studies in bio-
similar development and evaluation needs to be improved. 
“The gold standard of clinical trials does not hold true for 
biosimilars, where the focus is on analytical techniques that 
allow to obtain a high level of understanding about how the 
molecule works”. It was argued that this requires a mindset 
shift, as physicians are accustomed to the approval of new 
medicines, which undergo extensive clinical testing in phase 
I, II and III trials. Interviewees mentioned that many physi-
cians are still arguing that there are too few clinical trials 
conducted for biosimilars, demonstrating that the concept of 
biosimilar development is not clear to all involved. “Doctors 
are trained to say: they don’t have the clinical trials, they 
didn’t do the effort”. Awareness and understanding about 
the development steps prior to the clinical part was deemed 
lacking: “Physicians need to learn that the clinical trial is 
the cherry on the cake, a confirmatory step of biosimilarity 
demonstrated in earlier development steps”.
Informing physicians about the framework through which 
biosimilars are evaluated was seen as key in increasing their 
and by extension also their patients’ trust in biosimilars. 
Regulators argued that stakeholders must be informed that 
“phase III trials are a rather blunt tool to detect potential dif-
ferences, and more attention is paid towards the more sensi-
tive PK/PD trial” and that the clinical programme is tailored 
towards the goal of the biosimilarity exercise, not a shortcut 
for developers, which may not be well understood by all. It 
should be explained that tailoring allows avoiding unnec-
essary delays, patient participation and development costs.
3.2.1.2 Extrapolation of  Indications—Conveying Trust 
in  the  European Medicines Agency (EMA)’s Evaluation It 
was mentioned that the concept of extrapolation of indica-
tions, albeit an imperative part of biosimilar development, 
is often misunderstood by stakeholders. Overall, it was 
stressed that extrapolation should be trusted as a scientifi-
cally valid part of a rigorous registration procedure. “Trust 
in the approval pathway also means applying the concept 
of extrapolation of indication.” One pharmacist mentioned 
that the decision regarding extrapolation is the regulator’s 
expertise field and should not be further questioned: “As a 
pharmacist, I rely at what the EMA decides. I trust that what 
is decided is based on decent evidence.” Although several 
nurses expressed some hesitations, the overall concept and 
application was accepted. “Someone else has decided that it 
is OK, so I don’t think any of us can say that more needs to 
be done”. Among patients, opinions varied about the appli-
cation of extrapolation, ranging from trusting the EMA’s 
evaluation and mentioning that doing more than what scien-
tifically would be needed should be avoided, to considering 
it as shortcut for developers.
Regulators indicated that it should be explained to stake-
holders that extrapolation is not granted automatically and 
that exceptions can be applied if the studied indication 
would not be clinically representative or if questions about 
the mechanism of action across indications exist. A few 
pharmacists argued that regulators could “speak louder” 
about what extrapolation of indications entails. Interviewees 
generally believed that education on the biosimilar regula-
tory approval pathway is needed to further instil trust in 
extrapolation among stakeholders.
3.2.1.3 Interchangeability—A Need For  One‑Voice Guid‑
ance From Regulators Table 1 provides definitions and con-
siderations on interchangeability, switching and substitution 
in Europe.
Most pharmacists opined that a registered biosimilar 
could be considered interchangeable with its reference 
product. “If you establish this level of analytical similar-
ity, together with a clinical study in a reference indication, 
with the same mechanism of action, then for me, there is no 
discussion about interchangeability.” Most physicians cor-
roborated this opinion and believed that interchangeability 
between biosimilars and reference products is supported by 
788 L. Barbier et al.
the accumulated body of switch studies. Opinions of patients 
varied, ranging from a need for more data to agreeing with 
the physician’s decision. Regulators explained that addi-
tional clinical data, besides those requested in the registra-
tion procedure, are not needed from a scientific perspec-
tive, explaining why an interchangeability designation route 
imposing additional regulatory requirements as employed by 
the Food and Drug Administration (FDA) [47] was not cho-
sen in Europe. Although regulators explained that the man-
date to regulate substitution lies outside the EMA’s remit 
and therefore the EMA does not provide guidance on inter-
changeability, approved biosimilars are considered inter-
changeable. It was mentioned that individual members of 
the Biosimilar Medicinal Products Working Party (BMWP) 
published a position paper about interchangeability [48], 
striving to provide guidance on a European level.
Some interviewees argued that the current divergent 
approach regarding interchangeability between the FDA 
and the EMA creates distrust among stakeholders. The FDA 
framework was believed to imply that some biosimilars are 
more similar to the reference product than others. Further, 
heterogeneity between the positions of National Compe-
tent Authorities (NCAs) regarding interchangeability was 
believed to lead to confusion.
Several physicians and pharmacists mentioned that it 
would be preferable for the EMA to address interchange-
ability by providing a clear position or by requesting switch 
studies as part of the registration procedure, similar to the 
FDA’s approach. A few physicians advocated that this would 
encourage developers to conduct one methodologically 
robust study, which would be preferred over the scattered 
landscape of smaller, real-world switch studies. One inter-
viewee argued that this would settle the switch discussion 
before biosimilar market entry.
Regulators deemed interchangeability studies to require 
unnecessary time (delay in access) and financial invest-
ments, imposing additional challenges for biosimilar 
developers. Further, some regulators questioned how the 
FDA will address interchangeability over the product’s life 
cycle. Echoing the regulators’ viewpoint, some pharma-
cists deemed interchangeability studies a loss of time and 
resources, whereas others were in favour of extra data about 
Table 1  Interchangeability, switching and substitution in Europe: overview of terminology and considerations
EMA European Medicines Agency, EU European Union, FDA US Food & Drug Administration, US United States
European context • The EMA does not regulate interchangeability, switching and substitution of a reference medicine by its biosimilar. 
In the EU, prescribing practices and advice to prescribers fall under the responsibility of Member States. As such, 
decisions and guidance regarding interchangeability, switching and substitution fall within the remit of the EU 
Member States (i.e. taken at a national level) [2]
Interchangeability • “Refers to the possibility of exchanging one medicine for another medicine that is expected to have the same 
clinical effect. This could mean replacing a reference product with a biosimilar (or vice versa) or replacing one 
biosimilar with another.” [2]
• Replacement can be done by switching or substitution [2]
• Although there is no official position on interchangeability at the EU level, a paper by European regulators, 
members of the Biosimilar Medicinal Products Working Party, opines that biosimilars licensed in the EU can be 
considered interchangeable [48]
Switching • “When the prescriber decides to exchange one medicine for another medicine with the same therapeutic intent.” 
[2]
• Over previous years, concerns were raised around the safety of switching, arguing that switching patients to highly 
similar but not identical versions of the same product may lead to increased immunogenicity. Based on the available 
data (178 studies involving a switch between reference product and biosimilar) there are no indications that switch-
ing is related to any major efficacy, safety or immunogenicity issues [60] and switching between reference products 
and biosimilars has become part of routine clinical practice.
• Several national competent authorities have taken national positions endorsing switching between reference biologi-
cals and biosimilars [48, 62]
(Automatic) substitution • “The practice of dispensing one medicine instead of another equivalent and interchangeable medicine at pharmacy 
level without consulting the prescriber.” [2]
• The practice of (automatic) substitution for biological medicines is generally not allowed or is advised against in 
most European countries. In some countries, such as France, it is allowed under special conditions (e.g. only for 
treatment-naïve patients), but not implemented in practice. Changes are planned to legislation in Germany and Nor-
way, which would allow (a selection of) biologicals to be substituted at pharmacy level [66]
Different approach in US • The FDA has created a dedicated regulatory pathway for the designation of interchangeability. Dedicated studies are 
requested to demonstrate interchangeability. The pharmacist would be allowed to substitute a prescribed reference 
product with the interchangeable biosimilar without intervention of the prescriber (if also allowed by state law). So 
far, there are no FDA-designated interchangeable biosimilars. It appears that no official filings for the designation 
have been made so far [47, 48, 60, 67, 68]
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sequential switching. Some interviewees believed that it is 
up to the physician to decide if they are comfortable with 
multiple exchanges. Some patients voiced concerns and 
argued that there is a lack of evidence to ensure the safety 
and efficacy of sequential switching.
Overall, interviewees deemed it important that robust 
records are maintained that allow adequate traceability in 
case any signals would emerge and that random switches 
are avoided. Regulators emphasized that existing pharma-
covigilance systems should be able to capture any adverse 
drug reactions. It was mentioned that more attention needs 
to be paid to batch number recording.
3.2.1.4 Immunogenicity—Not a  Biosimilar‑Specific Con‑
cern Many pharmacists and physicians emphasized that 
stakeholders should learn that immunogenicity is not a bio-
similar-specific topic, as it could occur with any biological. 
“We need to explain what a biological is.” The immuno-
genicity topic is believed to have been fuelled by originator 
industry as an argument to instil fear and slow down biosim-
ilar acceptance, as mentioned by several physician and phar-
macist interviewees. “No one talked about immunogenicity 
issues before biosimilars arrived to the market”.
Further, some regulators and physicians argued that 
immunogenicity’s relevance depends on the molecule and 
that a risk-based assessment should be applied based on 
knowledge about the reference product. “I think that for the 
majority of biologicals immunogenicity is not so much a 
problem and definitely we shouldn’t make it one.”
Although immunogenicity assessment was believed to 
be addressed by the combination of a rigorous registra-
tion procedure and pharmacovigilance measures that allow 
longer-term monitoring, several interviewees suggested that 
improved traceability is needed to be able to attribute any 
possible immunogenicity signals to the involved product 
and batch. A few regulators mentioned that awareness of 
the importance of batch number reporting should be raised. 
Regulators also explained that stakeholders would benefit 
from knowing that immunogenicity is considered during 
biosimilar evaluation. A few interviewees anticipated that 
there could be an increase in immunogenicity reporting for 
biosimilars, as stakeholders tend to report more for ‘new’ 
products.
3.2.2  A Need for Education on Biological Medicines 
in General
In addition to continuing educating stakeholders about the 
scientific rationale behind the biosimilar regulatory approval 
process, several interviewees mentioned that educating 
stakeholders about biological medicines in general is neces-
sary. Creating awareness among HCPs about the existence of 
manufacturing changes over the lifecycle of any biological 
and knowledge about their inherent variability was believed 
to provide perspective that the reference product is also not 
identical over time and to be pivotal in helping stakehold-
ers understand the concepts behind biosimilarity. Increas-
ing awareness about these aspects among clinicians could 
generate understanding about variability between products 
and provide insight into the evaluation of these differences.
3.2.3  The Request for Regulatory Guidance About 
Switching
Most HCP interviewees indicated that information about 
considerations for biosimilar use, such as guidance about 
switching, is needed. To address questions regarding switch-
ing, it was argued that governments needs to take up a more 
active role in informing, educating and providing guidance 
about biosimilars to HCPs and patients. To this end, several 
physicians and pharmacists voiced that NCAs need to formu-
late clear statements about biosimilar use. The existing NCA 
guidance was generally considered too cautiously formulated 
and “not fully in touch” with practical realities by several 
HCPs. Some regulators also mentioned that most NCAs only 
address reference product to biosimilar switching, arguing 
that guidance needs to be deepened and broadened. Several 
interviewees argued that guidance about switching on an 
overarching European regulatory level would be preferred, 
as it is now left open to the individual NCAs, leading to 
differences in recommendations, impacting stakeholder 
trust and confidence. A regulator counterargued that trust 
in biosimilar use essentially has to be created by stakeholder 
education. A few interviewees cautioned that overarching 
guidance should not translate into forced switching and that 
the decision making should remain with the physician.
3.2.4  Real‑World Clinical Data Gathering to Instil Trust 
Among Stakeholders
Some physicians and nurses argued that real-world data 
could answer physicians’ demands for more clinical data, 
as it was argued to be reflective of clinical practice and often 
accompanied by expert opinion insights. Physicians and 
regulators indicated that switch study results can reassure 
physicians about switching. The NOR-switch trial [49] was 
raised as an example of such a post-approval initiative that 
increased physician confidence in biosimilars.
Clinical data gathering via registries was also consid-
ered to be helpful in increasing stakeholder confidence and 
reassuring stakeholders that the product performs well in 
every indication, instilling trust in extrapolation of indi-
cations. Further, registries were mentioned as gathering 
useful evidence about the long-term safety and efficacy of 
switching. In addition to clinical data, communication about 
790 L. Barbier et al.
real-life switch experiences was argued to be reassuring for 
stakeholders.
Several regulators cautioned that additional data-gather-
ing expectations from HCPs could pose a barrier for biosimi-
lar developers, as it requires sponsors to conduct expensive 
clinical studies beyond the licensing requirements and could 
also delay timely product uptake.
3.2.5  The Need for Practical and Stakeholder‑Oriented 
Information
Interviewees across stakeholder groups emphasized the need 
for practical information about biosimilar products and bio-
similar use.
Nurses believed that the information gap about biosimi-
lars among fellow nurses is high. Nurses mentioned the need 
for specific biosimilar training to increase their knowledge 
to be able to correctly address potential patient questions. 
Most nurses also wanted to receive training about switch 
management: “What does it mean for the patient, why are 
we switching, what are the benefits?”
Several nurses also indicated the need for timely infor-
mation about biosimilars entering the hospital. Organizing 
a product briefing session when a new product enters the 
hospital was suggested. Several interviewees mentioned that 
lessons should be derived from previous experiences, where 
switches were implemented without providing HCPs with 
necessary information. “One day we got the new medicine 
and we had to use it, change patients quickly without the 
right information, without a good answer why we needed 
to change”.
Several physicians also indicated that information should 
be tailored to the context in which the product is dispensed, 
that is, to the hospital or ambulatory setting and to the prod-
uct category.
In addition to information about practical use, pharma-
cists asked for practical product-specific information, such 
as information about differences and similarities in approved 
indications, presentations, packaging and, if applicable, 
injection devices between the reference product and its 
biosimilar(s). Additionally, information about the expected 
biosimilar pipeline was considered necessary to allow for 
timely procurement planning. Guidance about the construc-
tion of award criteria was also believed to be useful to sup-
port their work. A nurse mentioned that the number of dif-
ferent products that are available for the same medicine, with 
potential differences in names, devices and indications, can 
confuse patients and HCPs, also expressing the need for a 
clear overview of product characteristics.
Patients argued that information should be provided in a 
simple, understandable and accessible way, tailored to basic 
health literacy levels. Providing written information with 
graphics or video material were suggestions to improve 
patient information. Several patients mentioned that infor-
mation overshooting should be avoided, as not every patient 
is interested (“for many patients, it’s not an issue if it’s a bio-
similar or a regular biological”) and it could instill concerns 
among patients (“why is there so much attention about this?”).
Several patients explained that patient information should 
be tailored to “inform about what the patient actually needs 
and wants to know”, that is, informing about the implica-
tions for the patient. Further, it was emphasized that patients 
wish to be informed about any adverse event risk.
Several HCPs mentioned specific initiatives that helped 
to generate practical biosimilar guidance, such as the Dutch 
Association of Hospital Pharmacists (NVZA) toolbox [50] 
that provides practical switch guidance and the European 
Specialist Nurses Organisations (ESNO) biosimilar booklet 
[51] providing communication and information guidance for 
nurses.
3.2.6  The Need For Impartial and Homogenous 
Information
Across interviews, the importance of impartial information 
regarding biosimilars, originating from independent bodies 
such as the EMA and NCAs, was stressed. Also, regula-
tors believed that they are best suited to provide informa-
tion about biosimilars, acting from a neutral position with 
knowledge from actual biosimilar assessments. The EMA/
European Commission biosimilar stakeholder guidance 
documents [2, 52] were often mentioned during interviews 
as important and unbiased stakeholder information sources. 
One physician argued that awareness should be increased 
about the European Public Assessment Report, as it provides 
insights into regulatory evaluation and decision making.
Several interviewees across stakeholder groups consid-
ered that measures to actively counter misconceptions about 
biosimilars are necessary. Misconceptions were attributed 
by some to deceptive or commercially biased messaging by 
originator pharmaceutical industry protecting their market 
shares. “The issue is not so much the lack of information, but 
how the information is framed and presented”, “Companies 
have been successfully casting doubts about biosimilars”, “I 
don’t only need to educate, I have to dispel the angled infor-
mation that has been presented. I’m already fighting against 
the tide, before I start.” Patients and nurses also indicated 
that misconceptions about biosimilars, including considera-
tions about inferiority, should be tackled. Several regulators 
indicated that biosimilar regulatory concepts are misrep-
resented in an effort to set back stakeholder trust. Several 
interviewees advocated that existing sources should be inter-
preted with caution “to distinguish facts from nonsense”.
Convincing physicians who have been working with refer-
ence products for years appears to be challenging due to estab-
lished relations with pharmaceutical companies, as mentioned 
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by some interviewees. In contrast to most interviewees, several 
nurses identified pharmaceutical companies and their umbrella 
organizations as potential biosimilar educators.
Additionally, most regulators believed that “it’s not the 
lack of information, but the multitude and heterogeneity of 
information” that contributes to stakeholder misunderstand-
ing about biosimilars. This argument was also made by sev-
eral physicians, who mentioned that informational initiatives 
are scattered, leading to confusion, emphasizing the need for 
homogenous information.
3.2.7  Leading by Example—the Role of Key Opinion 
Leaders and Position Statements From Stakeholder 
Associations
Across all HCP stakeholder groups, interviewees mentioned 
that colleague key opinion leaders could play an important 
role in translating regulatory information into clear, concise 
statements, focused on practical considerations for biosimi-
lar use. Generally, information from within their own stake-
holder group (peer-to-peer information) was considered best 
suited and impactful to improve trust.
Several physician, regulator and patient interviewees advo-
cated that key opinion leaders are likely to be considered as a 
trustworthy information source. “Prominent physicians who 
have experience are the best ones to deliver the experience 
to their colleagues”. Biosimilar ambassadors could actively 
guide biosimilar implementation and inform colleagues. The 
conception of dedicated biologics/biosimilar expert offices on 
a local level was proposed as an alternative route to help pave 
the way. Additionally, physicians considered that experience 
sharing by clinical disciplines that are already exposed to bio-
similars could be leveraged to inform the next generation of 
stakeholders that will be confronted with biosimilars. Building 
from previous positive biosimilar experiences was argued to be 
an approach to increase trust by several interviewees. “It is a 
domino effect, when a few big hospitals are doing the switch, 
the others will follow.” “Once somebody else has done it, it 
takes some of the fear-factor away.”
Further, position statements by national and European 
scientific stakeholder associations were recognized as a lever 
to increase understanding among peers. It was remarked that 
continuous updating of position statements to reflect increas-
ing experience and knowledge about biosimilars is needed. 
The increasing endorsement of regulatory concepts, such as 
extrapolation of indications, by medical stakeholder associa-
tions was mentioned as a positive evolution in this context.
3.2.8  The Importance of Multi‑Stakeholder Aligned Efforts
Most interviewees across stakeholder groups advised that 
information and education should be a multi-stakeholder effort, 
ensuring that all stakeholders are able to communicate in the 
same way and can implement aligned decisions. Informing 
HCPs about biosimilars requires orchestrated action, initiated 
at regulatory approval, followed by information and guidance 
from the NCA and national scientific stakeholder associations 
upon national market entry. Specifically, regulators discussed 
that a more active collaboration between the EU and national 
regulatory authorities should be established, ensuring homog-
enous biosimilar information and targeted education streams. 
Further, a fostered collaboration between stakeholder groups 
was deemed necessary to translate regulatory information to 
stakeholder needs. Regulators and stakeholder organizations 
could write joint position papers, or information produced by 
the EMA could, after tailoring to the therapeutic area and stake-
holder needs, be used at a local level. Governmental support 
was deemed desirable and NCAs were believed to be best suited 
to organize neutral education events locally. Several physicians 
emphasized that NCAs, together with medical/scientific socie-
ties, should take up a more active role.
It was argued that communication should also be an 
orchestrated multi-stakeholder effort at a hospital level. This 
multidisciplinary approach was deemed especially necessary 
in the context of switch management. Several interviewees 
argued that hospital pharmacists would be best suited to guide 
these multi-stakeholder initiatives for HCP colleagues (e.g. 
via Drug & Therapeutics Committees), acting as ‘biosimilar 
educators’ and guiding biosimilar use in hospitals. Specialized 
nurses could in turn support patients when switching.
3.2.9  Ensuring Active Uptake of Information
Several interviewees mentioned that approaches to ensure 
active uptake of the provided information should be 
explored, as the existing information is believed to pen-
etrate the wider HCP and patient populations only slowly. 
Incorporating education on biosimilars in the stakeholder 
curricula was strongly supported across stakeholder groups. 
Suggestions were made to include biosimilar education as an 
obligatory part of the HCP accreditation system.
Gaining own practical experience with biosimilars in 
clinical practice (including switching) was also believed to 
establish trust among HCPs and patients by several inter-
viewees. “It is not very scientific, but that is how it works for 
physicians”. Gaining experience with switching to a biosimi-
lar was also argued to improve patient trust by some nurse 
interviewees: “Patients who tried the switch now accept it. 
They don’t think it is such a big thing anymore.”
4  Discussion
First, this study presented a structured review of the exist-
ing research on HCP and patient perceptions about biosimi-
lars, identifying a clear need for continued evidence-based 
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information and education initiatives to improve biosimilar 
understanding among HCPs and patients as knowledge about 
and acceptance of biosimilars is still variable and mostly 
unsatisfactory. Second, multi-stakeholder learnings and pro-
posed solutions on how to improve stakeholder understand-
ing and acceptance of biosimilars in Europe were gathered in 
semi-structured interviews with experts across stakeholder 
groups, reflecting the considerations of different stakehold-
ers involved. In contrast to the studies identified in the lit-
erature review that mostly focussed on measuring stakehold-
ers’ biosimilar knowledge, the qualitative part of this study 
identified expert insights on how to overcome stakeholder 
challenges to improve biosimilar understanding and adop-
tion. This study also captured insights of nurses, whose per-
spective generally has been underreported so far.
As discussed during the interviews, increasing biosimilar 
understanding and acceptance among stakeholders requires a 
multifactorial and interdisciplinary approach. No silver bul-
let solution exists; rather, a coordination of efforts of differ-
ent stakeholder levels is needed. Based on the synthesized 
study findings, we propose actions to be centred around ten 
actionable multi-stakeholder recommendations, which are 
Table 2  Multi-stakeholder recommendations—key points for decision makers and HCPs in Europe
Tailoring of strategies to the specific treatment setting, the product type and stakeholder needs is desirable
EMA European Medicines Agency, HCPs healthcare professionals
1.   Investing in education and information initiatives about biosimilars, explaining the scientific rationale behind the regulatory approval 
pathway for biosimilars and conveying trust in the regulatory evaluation by independent, governmental and regulatory bodies, further 
continuing and complementing the efforts made by European regulators, and other scientific organizations, over previous years in providing 
unbiased information to the public
2.   Investing in education about biological medicines in general and concepts such as comparability demonstration in the context of manufac-
turing changes, product characterization, immunogenicity and batch-to-batch variability (and methods to cope with this). HCP training should 
also include courses on drug development, including clinical trial design
3.   Developing clear and unified EU-overarching regulatory guidance about interchangeability and switching
   a. Continued regulatory guidance development about biosimilar use on both a national and European level
   b.  Collaboration between the EMA and the national competent authorities to provide one-voice guidance about interchangeability and 
switching
4.   Disseminating real-world clinical data about biosimilar use and switching via university or non-commercial-based educational 
outreach (academic detailing), key opinion leaders and peer-to-peer communication. Government and competent authorities should col-
laborate with scientific/medical stakeholder associations to develop and support such initiatives
5.   Sharing stakeholder experiences with biosimilar use and switching via academic detailing, key opinion leaders and via peer-to-peer 
communication. Government and competent authorities should collaborate with scientific/medical stakeholder associations to develop and 
support such initiatives
6.   Developing and providing product horizon scanning and practical biosimilar product-specific information (structured product over-
views with similarities and differences in product features of available options) on regional or national governmental level to support hospi-
tals and HCPs with biosimilar implementation
7.   Developing guidance about biosimilar use in practice to support HCPs. Existing initiatives and materials could be used as an example 
and tailored to the national/regional/setting-specific context
   a. Adapting clinical guidelines to reflect biosimilar use
   b. Developing HCP guidance about biosimilar use in clinical practice
   c. Developing a structured switch protocol
   d. Appointing coordinators to guide biosimilar implementation in clinical practice
   e. Developing patient information about any practical implications
8.   Designating an independent governmental body to actively monitor and correct biosimilar miscommunication/misconceptions, and 
address stakeholder queries in this regard (serving as a dedicated point of contact)
9.   Fostering multi-stakeholder initiatives and collaboration
   a.  Fostering collaboration between regulatory authorities and scientific/medical stakeholder associations to translate regulatory guid-
ance into practical information for HCPs and patients and to establish endorsement about biosimilar concepts by scientific stakeholder 
organizations. Position statements should be updated regularly to reflect the evolving knowledge and experience with biosimilars
   b.  Organizing biosimilar informational and educational efforts from a multi-stakeholder perspective, aligning the information between the 
involved stakeholder groups
   c. Governmental support and proactive approach needed
10. Organizing efforts in such a way that ensures active uptake of information and education
   a. Including courses in the curriculum of future HCPs
   b. Including courses in the mandatory continuous education (via accreditation programmes) of practicing HCPs
   c.  Proactively offering solution-oriented information and practical support programmes on a local level, which can be tailored to the 
needs of the stakeholder (i.e. educational and support programmes to the hospital at the time of new biosimilar introduction)
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presented in Table 2. These recommendations can inform 
policy making and other stakeholder initiatives to increase 
biosimilar understanding.
As recognized by the interviewees, extensive efforts 
have been made by European regulators to provide clear 
information regarding biosimilars and the science behind 
the regulatory evaluation to the public [2, 52–57]. Invest-
ments in providing unbiased biosimilar information and 
conveying trust in the regulatory evaluation must be con-
tinued (recommendation 1) to further improve stakeholder 
understanding. In particular, efforts to make this information 
more widely known to the target audience and to stimulate 
its active uptake are necessary (recommendation 10). To this 
end, biosimilar education should be included in both the cur-
ricula of future HCPs and in mandatory continuous learning 
programmes of practicing HCPs. Further, solution-oriented 
information programmes could be offered to HCPs to sup-
port them with biosimilar implementation at a local level. 
In the Netherlands, the Ministry of Health has subsidized 
such a biosimilar implementation programme that provides 
tailor-made support to hospitals [58, 59].
The basic training of HCPs should also focus on strength-
ening HCPs’ knowledge regarding biologics in general (rec-
ommendation 2), as some misconceptions regarding biosimi-
lars may stem from a limited understanding about biologics. 
Further, HCP training should be enhanced by courses on 
drug development.
In addition to including biosimilar education in continu-
ous learning programmes, sharing real-world clinical data 
about biosimilar use and switching may be effective to 
increase trust and acceptance among practicing HCPs (rec-
ommendation 4). Stakeholders indicated being reassured 
with regard to the safety of switching by the considerable 
number of switch studies that have been conducted over the 
last few years [60, 61]. Also, stakeholder experiences with 
biosimilar use should be actively disseminated via university 
or non-commercial-based educational outreach, key opinion 
leaders, and peer-to-peer communication to build trust (rec-
ommendation 5).
The EMA has no official position on interchangeability as 
prescribing practices and advice to prescribers fall under the 
responsibility of Member States [2]. Several Member States 
have released clear statements regarding interchangeability 
and switching [62]. An official, harmonized European regu-
latory position regarding interchangeability is believed to be 
needed, however, to provide clear and one-voice guidance 
to stakeholders across Member States. This will require a 
coordinated initiative and action between Member States 
and the EMA (recommendation 3).
On a practical level, stakeholders should be supported 
with product horizon scanning and structured product over-
views to ensure timely and efficient biosimilar implemen-
tation (recommendation 6). Guidance materials, such as 
switch protocols, should be provided to support hospitals 
and HCPs at a local level (recommendation 7). Existing 
materials [50, 51, 58, 59, 63] could serve as examples and 
be tailored to the specific context.
The knowledge gap and misunderstanding among HCPs 
and patients has likely been amplified by the (in some cases 
intentional) dissemination of misinformation on biosimilars. 
Biosimilar misinformation exists in many forms, ranging 
from presenting factually incorrect information to nega-
tively framing factually correct statements [64]. As shown 
in this study, industry involvement (from both originator and 
biosimilar manufacturers) in biosimilar stakeholder-related 
research is common (about one third of biosimilar stake-
holder studies were either industry sponsored or conducted 
by industry). At times, originator industry involvement may 
have resulted in a more cautious or misleading representa-
tion of results to discourage biosimilar use. The originator 
industry’s reach may further trickle down via relations with 
or by actively involving opinion leaders and prescribers to 
amplify misconceptions and concerns, and as such creating 
uncertainty among their peers. In addition to providing accu-
rate and unbiased information to stakeholders, biosimilar 
misinformation should be actively countered. Independent 
governmental bodies can act as designated entities to moni-
tor and correct biosimilar misinformation, and address stake-
holder queries in this regard (recommendation 8). Further, 
position statements from medical societies regarding bio-
similar use should be regularly updated to reflect the evolv-
ing knowledge and experience with biosimilars. Continuing 
to foster the collaboration and dialogue between regulatory 
authorities and medical stakeholders can support this (rec-
ommendation 9) [65].
The second article of this series provides recommenda-
tions on how to improve biosimilar use in clinical practice 
and focusses on elements such as switching [8].
Whereas this study specifically aims to inform the Euro-
pean context, recommendations may be applicable on a 
wider scale, taking necessary tailoring to regional, cultural 
and policy specificities into account. Results from studies 
conducted in different regions of the world (Fig. 1) show 
that the main challenges with biosimilar stakeholder under-
standing are generally similar across jurisdictions. As most 
interviewed participants represent a Western European per-
spective, some findings may not be reflective of the needs 
of regions where, for example, accessibility is more chal-
lenging and therefore of greater concern. Shared expert 
insights mainly related to the experience with and consid-
erations for anti-tumour necrosis factor products. Further, 
as most biological medicines are administered in or dis-
pensed via the hospital, interview discussions predomi-
nately focussed on the hospital context and as such no pub-
lic pharmacists were interviewed. Future research aimed at 
identifying specific learnings applicable to biosimilar use 
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in ambulatory care would be useful as, in contrast with 
the hospital setting where decisions are generally driven 
by tenders and involve a drug formulary committee, here 
the decision to use biosimilars is generally based on indi-
vidual prescriber perceptions. Tailoring of strategies to the 
treatment setting (hospital vs ambulatory care, chronic vs 
shorter term treatment), product type (more simple bio-
logicals vs complex monoclonal antibodies) and patient’s 
needs is desirable.
Realising the structural, multi-stakeholder recommenda-
tions outlined in this study to improve biosimilar acceptance 
will require a proactive approach and a combination of gov-
ernmental actions and policy measures on both a national 
and pan-European level.
5  Conclusion
Measures are needed to improve understanding and will-
ingness to use biosimilars among stakeholders, in order to 
capture the biosimilar competition potential and its societal 
and patient benefits. The actionable recommendations pro-
posed in this article can guide policy making and multi-
stakeholder initiatives to improve stakeholder understand-
ing about biosimilars. Providing stakeholders with objective 
information about the biosimilar approval pathway, ensuring 
active information uptake, dispelling biosimilar misinforma-
tion, providing product horizon scanning and communicat-
ing biosimilar implementation experiences are among the 
suggested actions.
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